Arbutus Biopharma Corporation (ABUS) Deep Dive Video

Summary

Arbutus offers an asymmetric biotech setup: a debt-free balance sheet, validated LNP patent monetization, and a competitive hepatitis B cure candidate priced below its legal and clinical optionality.

View ABUS stock page · Read the ABUS research report

Loading the video player…